Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(6 sites)
United States
USA04-0, Los Angeles, California Site USA06-0, Pittsburgh, Pennsylvania USA03-0, San Antonio, Texas Australia
AUS01-0, Randwick, New South Wales